Peripheral T‐cell lymphomas (PTCL) have suboptimal outcomes using conventional CHOP
(cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy. The anti‐folate
pralatrexate, the first drug approved for patients with relapsed/refractory PTCL, provided a
rationale to incorporate it into the front‐line setting. This phase 2 study evaluated a novel
front‐line combination whereby cyclophosphamide, etoposide, vincristine and prednisone
(CEOP) alternated with pralatrexate (CEOP‐P) in PTCL. Patients achieving a complete or …

Background Peripheral T-cell lymphomas (PTCL) are a heterogeneous group of non-
Hodgkin's lymphomas (NHL) characterized by poor treatment outcomes with conventional
chemotherapy, including CHOP [complete remission (CR)∼ 40%]. Retrospective studies
suggest that the incorporation of etoposide into chemotherapy regimens may improve
outcomes compared to CHOP. In contrast, anthracyclines appear to have a limited role in
PTCL, largely attributed to p-glycoprotein related resistance. Pralatrexate was the first drug …